A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 16, 2008

Primary Completion Date

September 29, 2009

Study Completion Date

September 29, 2009

Conditions
Ankylosing Spondylitis
Interventions
DRUG

ARRY-371797, p38 inhibitor; oral

multiple dose, single schedule

DRUG

Placebo; oral

matching placebo

DRUG

Placebo; oral

multiple dose, single schedule

Trial Locations (12)

29406

Low Country Rheumatology, Charleston

60611

Northwestern University, Chicago

68114

Westroads Medical Group, Omaha

73112

Lynn Health Science Institute, Oklahoma City

90048

Cedars-Sinai Medical Center, Los Angeles

97239

Oregon Health & Science University, Portland

99204

Arthritis Northwest, Spokane

T5M 0H4

Rheumatology Research Associates Group, Edmonton

R3A 1M4

University of Manitoba, Winnipeg

L5M 2V8

Credit Valley Rheumatology, Mississauga

G8Z IY2

Center de Recherche Musculo-Squelettique, Trois-Rivières

S7N 0W8

University of Saskatchewan, Saskatoon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00811499 - A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter